Hematological MalignancyChronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin
Section snippets
Isolation of CLL cells from peripheral blood
Five milliliters of total blood from CLL patients were drawn in heparinized glass tube for routine laboratory evaluation of blood chemistry and cellularity. All samples selected for this study contained high peripheral lymphoid cell counts (>20 × 103/μL). The superfluous material, usually between 1 and 2 mL, was shipped from the clinical centers to the Karolinska Laboratory by overnight mail at room temperature. The blood was diluted with equal volumes of phosphate-buffered saline and tumor
A new in vitro drug-sensitivity assay
CLL cells rapidly undergo apoptosis when cultured in vitro in conventional cell culture medium, which contrasts with their prolonged survival in vivo [26]. In this respect, CLL cells are similar to normal peripheral blood B cells. In vitro survival of B cells is mainly determined by the availability of the proper mixture of cytokines. Peripheral blood B cells and CLL B cells produce and secrete similar amounts of cytokines and cytokine receptors in vitro [27]. Depletion of cytokine-mediated
Discussion
Chronic lymphoid leukemia cells are favorite targets of in vitro chemosensitivity and chemoresistance assays due to easy availability in large quantities in the peripheral blood of CLL patients. These assays, however, are complicated by the limited survival of the lymphoma cells outside of the body, as well as by difficulty comparing in vitro and in vivo response rates. In the present article, we used a new in vitro cell culture system that maintains the composition of whole human blood but at
Acknowledgments
This work was supported by the Swedish Research Council, the Swedish Cancer Fund and Karolinska Institute Strategic Fund.
References (39)
- et al.
Clinical staging of chronic lymphocytic leukemia
Blood
(1975) - et al.
Chronic lymphocytic leukemia: diagnosis and treatment
Mayo Clin Proc
(2006) - et al.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Blood
(2008) - et al.
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis
Blood
(1996) - et al.
Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells
Blood
(2005) - et al.
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
Blood
(2009) - et al.
NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab
Biomed Pharmacother
(2009) - et al.
Animal models for chronic lymphocytic leukemia
J Cell Biochem
(2007) - et al.
Chronic lymphocytic leukaemia
Anticancer Res
(2009) - et al.
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells
J Exp Med
(2001)
A clinical staging system for chronic lymphocytic leukemia: prognostic significance
Cancer
Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway
Leuk Lymphoma
The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia
Leukemia
Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
Br J Haematol
Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair
Leukemia
Fludarabine in the treatment of chronic lymphocytic leukemia: a review
Ther Clin Risk Manag
Rediscovering alemtuzumab: current and emerging therapeutic roles
Br J Haematol
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy
Leukemia
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication
Clin Cancer Res
Cited by (12)
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study
2016, Experimental HematologyCitation Excerpt :All tests were carried out in an optimized primary cell culture medium (OmniSanguine) that prevented early apoptosis of CLL cells, thus allowing long enough culturing to evaluate the full effects of the investigated drugs, including those with less pronounced cytotoxicity. The preserved viability of the CLL cells in this medium is well established [10,11,21], and our comparative analysis with RPMI medium confirms this. Refractoriness to one type of cytostatic agent may be associated with refractoriness to others, [11].
The D ~ Sense ex-vivo viability assay application in a patient with stage IV lung adenocarcinoma: a case report
2023, Journal of Medical Case ReportsApplication of high-throughput drug sensitivity screening system in the treatment of non-small cell lung cancer with malignant pleural effusion
2022, Journal of Shanghai Jiaotong University (Medical Science)